Acute and long-term safety and tolerability of risperidone in children with autism

Journal of Child and Adolescent Psychopharmacology

Volumn 15, Issue 6, 2005, Pages 869-884

  Aman, Michael G ^a,j   Arnold, L Eugene ^a   McDougle, Christopher J ^b   Vitiello, Benedetto ^c   Scahill, Lawrence ^d   Davies, Mark ^e   McCracken, James T ^f   Tierney, Elaine ^g   Nash, Patricia L ^h   Posey, David J ^b   Chuang, Shirley ^e   Martin, Andres ^d   Shah, Bhavik ^f   Gonzalez, Nilda M ^g   Swiezy, Naomi B ^b   Ritz, Louise ^c   Koenig, Kathleen ^d   McGough, James ^f   Ghuman, Jaswinder K ^g   Lindsay, Ronald L ⁱ  

^a OHIO STATE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d YALE UNIVERSITY   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g KENNEDY KRIEGER INSTITUTE   (United States)

^h NATIONWIDE CHILDREN S HOSPITAL   (United States)

ⁱ Arizona Child Study Center   (United States)

^j THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RISPERIDONE;

ADOLESCENT; ANXIETY; APPETITE DISORDER; AROUSAL; ARTICLE; AUTISM; BALANCE DISORDER; BODY MASS; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ELECTROLYTE BALANCE; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; GYNECOMASTIA; HUMAN; HYPERSALIVATION; INSOMNIA; LABORATORY DIAGNOSIS; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUSCLE DISEASE; NAUSEA; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; SCORING SYSTEM; SEIZURE; SLEEP PATTERN; SOMNOLENCE; STANDARDIZATION; STATISTICAL SIGNIFICANCE; TACHYCARDIA; TONGUE DISEASE; TREATMENT FAILURE; URINALYSIS; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; BODY MASS INDEX; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DISORDERS OF EXCESSIVE SOMNOLENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LONG-TERM CARE; MALE; RISPERIDONE;

EID: 29944444165     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2005.15.869     Document Type: Article

References (25)

1. Aman MG, DeSmedt G, Derivan A, Lyons B, Findling RL, Risperidone Disruptive Behavior Study Group: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1347, 2002.
2. Aman MG, Lam KSL, Collier-Crespin A: Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society in Ohio. J Autism Dev Disord 33:527-534, 2003.
3. Aman MG, Singh NN: Aberrant Behavior Checklist Manual. East Aurora, NY: Slosson Educational Publications, 1994.
4. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity: Consensus development conference on antipsychotic drugs and obesity and diabetes. Diab Care 27:596-601, 2004.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association, 1994.
6. Arnold LE, Aman MG, Martin A, Collier-Crespin A, Vitiello B, Tierney E, Asarnow R, Bell-Bradshaw F, Freeman BJ, Gates-Ulanet P, Klin A, McCracken JT, McDougle CJ, McGough JJ, Posey DJ, Scahill L, Swiezy NB, Ritz L, Volkmar F: Assessment in multisite randomized clinical trials of patients with autistic disorder: The Autism RUPP Network. J Autism Dev Disord 30:99-111, 2000.
7. Gadow KD, Sprafkin J: Manual for Stony Brook Child Symptom Inventories. Child Symptom Inventory: Parent Checklist. Child Symptom Inventory: Teacher Checklist. Stony Brook, NY: Checkmate Plus, 1994.
8. Greenhill LL, Vitiello B, Riddle MA, Fisher P, Shockey E, March JS, Levine J, Fried J, Abikoff H, Zito JM, McCracken JT, Findling RL, Robinson J, Cooper TB, Davies M, Varipatis E, Labellarte MJ, Scahill L, Walkup JT, Capasso L, Rosengarten J: Review of safety assessment methods used in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 42:627-633, 2003.
9. Handen BL, Feldman H, Gosling A, Breaux AM, McAuliffe S: Adverse side effects of methylphenidate among mentally retarded children with ADHD. J Am Acad Child Adolesc Psychiatry 30:241-245, 1991.
10. Ioannidis JPA, Lau J: Completeness of safety reporting in randomized trials: An evaluation of seven medical areas. JAMA 285:437-443, 2001.
11. Langworthy-Lam KS, Aman MG, Van Bourgondien ME: Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. J Child Adolesc Psychopharmacol 12:311-321, 2002.
12. Lindsay RL, Leone S, Aman MG: Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clin Pediatr 43:437-444, 2004.
13. Lord C, Rutter M, LeCouteur A: Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659-685, 1994.
14. Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CM, Tierney E, Chuang S, Vitiello B, and the Research Units on Pediatric Psychopharmacology Autism Network: Weight and leptin changes among risperidone-treated youths with autism: Six-month prospective data. Am J Psychiatry 161(6):1125-1127, 2004.
15. National Institute of Mental Health: Abnormal Involuntary Movement Scale (AIMS). Psychopharmacol Bull (Special feature: Rating scales and assessment instruments for use in pediatric psychopharmacology research) 21:1077-1080, 1985a.
16. National Institute of Mental Health: CGI (Clinical Global Impression Scale). Psychopharmacol Bull 21:839-844, 1985b.
17. Research Units on Pediatric Psychopharmacology Autism Network: Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314-321, 2002.
18. Research Units on Pediatric Psychopharmacology Autism Network: Risperidone treatment of autistic disorder: Longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162:1361-1369, 2005.
19. Scahill L, McCracken J, McDougle CJ, Aman M, Arnold LE, Tierney E, Cronin P, Davies M, Ghuman J, Gonzalez N, Koenig K, Lindsay R, Martin A, McGough J, Posey DJ, Swiezy N, Volkmar F, Ritz L, Vitiello B: Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. J Child Adolesc Psychopharmacol 11:377-388, 2001.
20. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19, 1970.
21. Snyder R, Turgay A, Aman M, Binder C, Fisman S, Carroll A, and the Risperidone Conduct Study Group: Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 41:1026-1036, 2002.
22. Stigler KA, Potenza MN, McDougle CJ: Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 3:927-942, 2001.
23. Tandon R: Safety and tolerability: How do newer generation "atypical" antipsychotics compare? Psychiatr Q 73:297-311, 2002.
24. Vitiello B, Riddle MA, Greenhill LL, March JS, Levine J, Schachar RJ, Abikoff H, Zito JM, McCracken JT, Walkup JT, Findling RL, Robinson J, Cooper TB, Davies M, Varipatis E, Labellarte MJ, Scahill L, Capasso L: How can we improve the assessment of safety in child and adolescent psychopharmacology? J Am Acad Child Adolesc Psychiatry 42:634-641, 2003.
25. Zito JM, Safer DJ, dosReis S, Gardner JF, Magder L, Soeken K, Boles M, Lynch F, Riddle MA: Psychotropic practice patterns for youth. Arch Pediatr Adolesc Med 157:17-25, 2003.